Cost-Effectiveness of Ofatumumab Plus Chlorambucil in First Line Chronic Lymphocytic Leukemia in Canada.

نویسندگان

  • W Herring
  • I Pearson
  • M Purser
  • H R Nakhaipour
  • A Haiderali
  • S Wolowacz
  • K Jayasundara
چکیده

Table 1. Drug Acquisition, Administration, and Monitoring Costs for FirstLine Treatment With OChl and Chl Cost Type OChl Chl Drug acquisition Ofatumumab, 100 mg vial $336 – Chlorambucil, 25 x 2 mg pack $35 $35 Administration Induction infusion in first cycle (O) $1,039 – Regular infusion in subsequent cycles (O) $818 – Oral chemotherapy dispensing (Chl)a $9 $9 Monitoring (per chemo cycle)b $119 $119 Premedications (per chemo cycle) $10 – aThe dispensing fee is per 6 months of drug. bCosts include hematologist visit, complete blood count, and biochemistry.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

New developments in the management of chronic lymphocytic leukemia: role of ofatumumab

Ofatumumab is one of the three anti-CD20 monoclonal antibodies currently available for the treatment of chronic lymphocytic leukemia (CLL). The US Food and Drug Administration (FDA) approved the use of ofatumumab in patients with CLL refractory to fludarabine and alemtuzumab in 2009, and the European Medicines Agency (EMA) granted approval for the same indication in 2010. Subsequent positive re...

متن کامل

Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia

Treatment aim for chronic lymphocytic leukemia has been radically changed over the past years from providing only a palliative approach to reaching disease eradication and improving survival. Ofatumumab is a monoclonal humanized antibody with peculiar in vitro and in vivo properties, at present approved for double fludarabine and alemtuzumab refractory chronic lymphocytic leukemia. Its efficacy...

متن کامل

A Systematic Review and Network Meta-Analysis to Evaluate the Comparative Efficacy of Interventions for Unfit Patients with Chronic Lymphocytic Leukemia

INTRODUCTION Rituximab plus fludarabine and cyclophosphamide (RFC) is the standard of care for fit patients with untreated chronic lymphocytic leukemia (CLL); however, its use is limited in 'unfit' (co-morbid and/or full-dose F-ineligible) patients due to its toxicity profile. We conducted a systematic review and Bayesian network meta-analysis (NMA) to determine the relative efficacy of commerc...

متن کامل

Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study

MABLE investigated the efficacy and safety of rituximab plus bendamustine or rituximab plus chlorambucil in fludarabine-ineligible patients with chronic lymphocytic leukemia. Patients received rituximab plus bendamustine or rituximab plus chlorambucil every four weeks for six cycles. Rituximab plus chlorambucil-treated patients without a complete response after Cycle 6 received chlorambucil mon...

متن کامل

[Monoclonal Antibodies in the Treatment of Chronic Lymphocytic Leukemia in 2015].

Chemotherapy combinations with monoclonal antibodies are now the basis for treatment of chronic lymphocytic leukemia. Rituximab, the most widely used anti-CD20 antibody in routine clinical practice, led not only to improvement of progression-free survival, but also to improvement of overall survival in previously untreated patients with good performance status in combination with fludarabine an...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

دوره 17 7  شماره 

صفحات  -

تاریخ انتشار 2014